enGene Therapeutics Inc
Company Profile
Business description
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Contact
4868 Rue Levy
Suite 220
Saint-LaurentQCH4R 2P1
CANT: +1 514 332-4888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
82
Stocks News & Analysis
stocks
ASX rare earths play looks to expand production
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
stocks
The 10 best US companies to invest in now
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 44.30 | 0.50% |
| CAC 40 | 7,845.89 | 11.79 | 0.15% |
| DAX 40 | 25,435.43 | 181.22 | 0.72% |
| Dow JONES (US) | 51,540.98 | 273.08 | 0.53% |
| FTSE 100 | 10,513.50 | 15.56 | 0.15% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,674.95 | 197.63 | 0.72% |
| Nikkei 225 | 70,683.98 | 737.12 | 1.05% |
| NZX 50 Index | 13,700.12 | 1.10 | 0.01% |
| S&P 500 | 7,824.81 | 50.86 | 0.65% |
| S&P/ASX 200 | 8,735.70 | 49.30 | 0.57% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |